The role of FGFR2 amplification and expression in patients with advanced or metastatic gastric cancer receiving fluoropyrimidine-based chemotherapy

被引：0
|
作者：
Skupinska, M. M. [1 ]
Jesiotr, M. [2 ]
Chrom, P. [3 ]
Mroz, A. [4 ]
Cierniak, S. [2 ]
Winiarek, M. [5 ]
Wyrwicz, L. S. [5 ]
Pieczykolan, J. [6 ]
Wieczorek, M. [7 ]
Stanczak, A. [1 ]
Bodnar, L. [3 ]
机构：
[1] Celon Pharma, Preclin Dev Dept, Warsaw, Poland
[2] Mil Inst Med, Dept Pathol, Warsaw, Poland
[3] Mil Inst Med, Dept Oncol, Warsaw, Poland
[4] M Sklodowska Curie Mem Canc Ctr & Inst Oncol, Dept Pathol & Lab Diagnost, Warsaw, Poland
[5] M Sklodowska Curie Mem Canc Ctr & Inst Oncol, Dept Oncol & Radiotherapy, Warsaw, Poland
[6] Celon Pharma, Preclin Dev Dept, Lomianki, Poland
[7] Celon Pharma SA, Lomianki, Poland
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
647P
引用
收藏
页码：218 / 218
页数：1
相关论文
共 50 条
  • [31] Incidence of hand–foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen
    Carlos Gómez-Martin
    Antonio Sánchez
    Antonio Irigoyen
    Beatriz Llorente
    Begoña Pérez
    Raquel Serrano
    Mª José Safont
    Esther Falcó
    Adelaida Lacasta
    Margarita Reboredo
    Jorge Aparicio
    Rosario Dueñas
    Marta Llanos Muñoz
    Pilar Regueiro
    Elena Sanchez-Viñes
    Rafael López López
    Clinical and Translational Oncology, 2012, 14 : 689 - 697
  • [32] The efficacy of fluoropyrimidine-based second line chemotherapy in advanced and metastatic pancreatic cancer: Results of an ongoing retrospective multicenter study
    Mancuso, A.
    Saletti, P.
    Sacchetta, S.
    Romagnani, E.
    Aprile, G.
    Fatigoni, S.
    Garassino, M.
    Saggese, M.
    Cavalli, F.
    Sternberg, C.
    ANNALS OF ONCOLOGY, 2006, 17 : 61 - 61
  • [33] Expansion part of phase I study of E7090 in patients with cholangiocarcinoma harboring FGFR2 gene fusion and with gastric cancer harboring FGFR2 gene amplification or FGFR2 protein high expression
    Morizane, Chigusa
    Ueno, Makoto
    Ioka, Tatsuya
    Tajika, Masahiro
    Ikeda, Masafumi
    Yamaguchi, Kensei
    Hara, Hiroki
    Yabusaki, Hiroshi
    Miyamoto, Atsushi
    Iwasa, Satoru
    Muto, Manabu
    Takashima, Tsutomu
    Minashi, Keiko
    Komatsu, Yoshito
    Nishina, Tomohiro
    Nakajima, Takako Eguchi
    Sahara, Takatoshi
    Funasaka, Setsuo
    Yashiro, Masakazu
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [34] Preoperative radiotherapy with concomitant fluoropyrimidine-based chemotherapy for resectable locally advanced rectal cancer
    Atasoy, Beste Melek
    Dane, Faysal
    Caglar, Hale
    Tezcanli, Evrim
    Cingi, Asim
    Abacioglu, Ufuk
    Turhal, Serdar
    Yegen, Cumhur
    TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2008, 23 (04): : 163 - 171
  • [35] The efficacy of fluoropyrimidine-based second line chemotherapy in advanced and metastatic pancreatic cancer: Results of an ongoing Italian multicenter survey
    Mancuso, A.
    Sacchetta, S.
    Tronconi, C.
    Aprile, G.
    Aglione, S.
    Fatigoni, S.
    Garassino, M. C.
    Saggese, M.
    Martelli, O.
    Saggia, C.
    Sternberg, C. N.
    ANNALS OF ONCOLOGY, 2006, 17 : XI51 - XI51
  • [36] Fluoropyrimidine-based chemotherapy for gastrointestinal cancer in patients with direct oral anticoagulants or warfarin
    Matsubara, Yuki
    Ando, Takayuki
    Sakumura, Miho
    Yoshita, Hiroki
    Nanjo, Sohachi
    Mihara, Hiroshi
    Fujinami, Haruka
    Tsukada, Kenichiro
    Shinya, Kajiura
    Ogawa, Kohei
    Hosokawa, Ayumu
    Terada, Mitsuhiro
    Yasuda, Ichiro
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis
    Zhu, Lucheng
    Liu, Jihong
    MA, Shenglin
    PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 853 - 861
  • [38] MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer
    Simmer, Femke
    Venderbosch, Sabine
    Dijkstra, Jeroen R.
    Vink-Borger, Elisa M.
    Faber, Claudius
    Mekenkamp, Leonie J.
    Koopman, Miriam
    De Haan, Anton F.
    Punt, Cornelis J.
    Nagtegaal, Iris D.
    ONCOTARGET, 2015, 6 (26) : 22996 - 23007
  • [39] SURAMIN IN PATIENTS WITH METASTATIC COLORECTAL-CANCER PRETREATED WITH FLUOROPYRIMIDINE-BASED CHEMOTHERAPY - A PHASE-II STUDY
    FALCONE, A
    PFANNER, E
    CIANCI, C
    DANESI, R
    BRUNETTI, I
    DELTACCA, M
    CONTE, PF
    CANCER, 1995, 75 (02) : 440 - 443
  • [40] Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer
    Whyte, S.
    Pandor, A.
    Stevenson, M.
    Rees, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 47 - 53
12345